Obstetrics & Gynecology:
Quality of Perioperative Venous Thromboembolism Prophylaxis in Gynecologic Surgery
Wright, Jason D. MD; Hershman, Dawn L. MD; Shah, Monjri MD; Burke, William M. MD; Sun, Xuming MS; Neugut, Alfred I. MD, PhD; Lewin, Sharyn N. MD; Herzog, Thomas J. MD
From the Departments of Obstetrics and Gynecology and Medicine, Columbia University College of Physicians and Surgeons, the Department of Epidemiology, Mailman School of Public Health, Columbia University, and the Herbert Irving Comprehensive Cancer Center, New York, New York.
See related editorial on page 973 and related article on page 1111.
Corresponding author: Jason D. Wright, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, 8th Floor, New York, NY 10032; e-mail: firstname.lastname@example.org.
Financial Disclosure The authors did not report any potential conflicts of interest.
OBJECTIVE: To estimate the use of venous thromboembolism prophylaxis in women undergoing gynecologic surgery and to estimate the patient, physician, and hospital characteristics associated with guideline-based prophylaxis.
METHODS: A commercial database was used to examine women who underwent major gynecologic surgery from 2000 to 2010. Venous thromboembolism prophylaxis was classified as none, mechanical, pharmacologic, or a combination. Multivariable logistic regression models of factors associated with any prophylaxis and pharmacologic and combination prophylaxis were developed.
RESULTS: We identified a total of 738,150 women who underwent gynecologic surgery. No prophylaxis was given to 292,034 (39.6%) women, whereas 344,068 (46.6%) received mechanical prophylaxis, 40,268 (5.5%) pharmacologic prophylaxis, and 61,780 (8.4%) combination prophylaxis. Use of prophylaxis increased from 53.5% in 2000 to 67.5% in 2010. Prophylaxis was more commonly used in older women, those with Medicare, women with more comorbidities, white women, patients treated at rural hospitals, teaching facilities, and in patients treated by high-volume surgeons and at high-volume centers (odds ratio [OR] 1.25, 95% confidence interval [CI] 1.23–1.27, P<.05 for all). Factors associated with use of pharmacologic prophylaxis included advanced age, white race, noncommercial insurance, later year of diagnosis, greater comorbidity, treatment at large hospitals and urban facilities, and treatment by a high-volume surgeon (OR 1.47, 95% CI 1.44–1.49).
CONCLUSION: Despite clear recommendations from evidence-based guidelines, venous thromboembolism prophylaxis is underused in women undergoing gynecologic surgery.
LEVEL OF EVIDENCE: III
Venous thromboembolism, including both pulmonary embolism and deep vein thrombosis (DVT), is a major cause of morbidity and mortality in patients undergoing surgery.1–3 In a pooled analysis of patients who underwent gynecologic surgery without venous thromboembolism prophylaxis, the reported rates of DVT ranged from 4% to 38% with an average of 16%.4 Fatal pulmonary emboli occur in 0.4% of patients.4 In addition to the substantial resource use for patients who develop a venous thromboembolism, patients with nonfatal thromboemboli are at risk for recurrent DVT or pulmonary embolus and postthrombotic syndrome. A number of risk factors, including advanced age, prior venous thromboembolism, cancer, and pelvic radiation, increase the risk of venous thromboembolism in patients undergoing gynecologic surgery.1,2,4
Given the catastrophic effects of perioperative thromboembolic disease, there is a strong rationale for prevention. A series of studies have suggested that venous thromboembolism prophylaxis is highly effective in the prevention of venous thromboembolism.1,2,4 For patients undergoing gynecologic surgery, both mechanical and pharmacologic methods of prophylaxis have been shown to effectively reduce the incidence of perioperative venous thromboembolism.5–10 In addition, a number of studies have shown that clinically meaningful bleeding with prophylactic doses of anticoagulation is uncommon.1
Given the abundance of data, a number of professional societies have developed evidence-based guidelines to facilitate appropriate thromboprophylaxis. The American College of Chest Physicians now recommends that all women who undergo major gynecologic surgery receive prophylaxis with unfractionated heparin, low molecular weight heparin, or intermittent pneumatic compression devices.1 The American College of Obstetricians and Gynecologists recommends unfractionated heparin, low molecular weight heparin, or pneumatic compression devices for patients at moderate or high risk who undergo gynecologic surgery. Graduated compression stockings are an alternative for moderate-risk patients.3
Despite the widespread availability of thromboprophylaxis guidelines, little is known about compliance with the recommendations in patients who undergo gynecologic surgery in the United States. For other surgical specialties, a number of studies have reported that the use of perioperative venous thromboembolism prophylaxis is poor.11–13 We performed an analysis to estimate the use of venous thromboembolism prophylaxis in women who underwent abdominal and vaginal surgery for benign disease and to estimate the patient, physician, and hospital characteristics associated with appropriate prophylaxis.
MATERIALS AND METHODS
The Perspective database was used. Perspective is a nationwide, voluntary, fee-supported database developed to measure quality, outcomes, and resource use. The database includes more than 500 acute-care hospitals located throughout the United States that contribute data on inpatient hospital admissions. Each participating institution submits electronic updates on a quarterly basis. The data are audited regularly to ensure quality and integrity. Perspective captures data on patient demographics, disease characteristics, procedures, and all billed services. As such, the database contains information on all drugs, devices, radiologic tests, laboratory tests, and therapeutic services rendered during a patient's hospital course. Perspective is validated and has been used in a number of outcomes studies.11,14–16 The study was approved by the Columbia University Institutional Review Board.
Patients who underwent gynecologic surgery for benign disease between 2000 and 2010 were analyzed. We selected patients who underwent the following procedures: abdominal hysterectomy (International Classification of Diseases, 9th Revision [ICD-9] 68.3, 68.39, 68.4, 68.9), vaginal hysterectomy (ICD-9 68.5, 68.59), salpingo-oophorectomy or cystectomy (ICD-9 65.22, 65.29, 65.3, 65.39, 65.4, 65.49, 65.5, 65.51, 65.52, 65.6, 65.61, 65.62), or colporrhaphy (ICD-9 70.5X). These procedures categories were not mutually exclusive and patients may have undergone multiple procedures. Patients who underwent a primary laparoscopic procedure were excluded. Patients with a diagnosis of cancer of the genitourinary tract were excluded and reported in a separate analysis.
Demographic data analyzed included age (younger than 40, 41–65 compared with older than 65 years of age), race (white, African American, other), year of diagnosis (2000–2003, 2004–2007 compared with 2008–2010), primary payer (Medicare, Medicaid, commercial insurance, uninsured), marital status (married compared with single), and length of stay (less than 3 days, 3–7 days, more than 7 days). Comorbidity was estimated using the Charlson index. The ICD-9 coding for calculation of the Charlson index was based on the classification system developed by Deyo and colleagues.17
Systems characteristics analyzed included geographic area (midwest, northeast, south, west), hospital location (urban compared with rural), hospital teaching status (teaching compared with nonteaching), and hospital size (less than 400, 400–600, greater than 600 beds). Annualized procedural volume was calculated to explore the effect of physician and hospital case volume on the use of prophylaxis. Each hospital or surgeon's annual case volume was estimated by dividing the number of patients who underwent surgery by the number of years an individual hospital or surgeon performed at least one procedure. The distribution of annual surgical volume was inspected visually and cut points selected to create tertiles of surgeon and hospital volume, each with similar numbers of patients; low-volume, intermediate-volume, and high-volume as has been reported in prior work.18,19
Each patient was classified based on the type of venous thromboembolism prophylaxis they received. Patients who had either graduated compression stockings or intermittent pneumatic compression devices were coded as mechanical prophylaxis. Patients who received unfractionated heparin, low molecular weight heparin (including enoxaparin sodium, tinzaparin sodium, or dalteparin sodium), or fondaparinux sodium were classified as having received pharmacologic prophylaxis. Patients who received mechanical prophylaxis in combination with pharmacologic prophylaxis were coded as having received combination prophylaxis.20 Two separate end points were analyzed. Any prophylaxis was defined as having received mechanical, pharmacologic, or combination prophylaxis. A second analysis was performed to specifically examine use of pharmacologic prophylaxis, which may consist of either pharmacologic prophylaxis alone or combination prophylaxis.
The association between patient, physician, and hospital characteristics and use of prophylaxis was examined using χ2 tests. Multivariable logistic regression models were developed to determine the use of prophylaxis while controlling for other patient, physician, and hospital characteristics. Separate models were developed to examine use of any prophylaxis and use of pharmacologic prophylaxis. P<.05 was considered statistically significant. All analyses were performed with SAS 9.2.
A total of 738,150 patients were identified. No venous thromboembolism prophylaxis was given to 292,034 (39.6%) women, whereas 344,068 (46.6%) had mechanical prophylaxis, 40,268 (5.5%) received pharmacologic prophylaxis, and 61,780 (8.4%) received combination (pharmacologic and mechanical) prophylaxis (Table 1). In a univariable analysis, patient characteristics associated with use of prophylaxis included older age, insurance coverage with Medicare, treatment more recently, hospitalization for more than 7 days, residence in the southern or midwestern United States, and greater medical comorbidity (P<.05 for all). Patients treated at rural hospitals, teaching facilities, and intermediate- and large-volume hospitals were more likely to receive prophylaxis (P<.05 for all). Among women treated at low-volume hospitals, 60.8% received prophylaxis compared with 59.4% of patients at high-volume hospitals (P<.001). Low-volume physicians administered venous thromboembolism prophylaxis in 58.2% of their cases, whereas high-volume physicians used prophylaxis in 63.5% of their patients (P<.001).
Figure 1 displays the use of prophylaxis based on the year of diagnosis. In 2000, 46.5% of patients received no prophylaxis. By 2010, 32.5% of patients did not receive any form of prophylaxis. Use of mechanical prophylaxis was 44.0% in 2000, peaked at 49.8% in 2006, and then decreased to 43.0% by 2010. Pharmacologic prophylaxis increased from 3.4% to 10.3% during the study period, whereas combination prophylaxis rose from 6.1% in 2000 to 14.2% in 2010.
Table 2 displays a multivariable logistic regression model of factors associated with any prophylaxis. Women older than 65 years of age (odds ratio [OR] 1.51, 95% confidence interval [CI] 1.47–1.55), those with Medicare (OR 1.12, 95% CI 1.09–1.14), patients with more than two comorbid conditions (OR 1.46, 95% CI 1.42–1.50), and those diagnosed from 2008 to 2010 (OR 1.81, 95% CI 1.79–1.84) were more likely to receive some form of prophylaxis, whereas African American women (OR 0.90, 95% CI 0.88–0.91) and single patients (OR 0.97, 95% CI 0.96–0.99) were less likely to receive prophylaxis. Patients treated at rural hospitals (OR 1.21, 95% CI 1.19–1.23), teaching hospitals (OR 1.03, 95% CI 1.02–1.05), and intermediate-sized facilities (OR 1.26, 95% CI 1.24–1.28) were more likely to receive prophylaxis, whereas patients in the northeast (OR 0.70, 95% CI 0.68–0.71) and west (OR 0.61, 95% CI 0.60–0.62) were less likely to receive prophylaxis. Patients treated by high-volume physicians (OR 1.02, 95% CI 1.00–1.03) and high-volume hospitals (OR 1.25, 95% CI 1.23–1.27) more often received some form of prophylaxis.
Factors associated with use of pharmacologic prophylaxis included advanced age (older than 65 years), white race, noncommercial insurance (Medicare, Medicaid, uninsured), later year of diagnosis, hospital stay more than 7 days, treatment in the northeast, and greater comorbidity (P<.05 for all) (Table 2). Patients treated at rural hospitals (OR 0.95, 95% CI 0.93–0.97) were less likely to receive pharmacologic prophylaxis, whereas women operated on at teaching hospitals (OR 1.34, 95% CI 1.32–1.37) and larger facilities (OR 1.08, 95% CI 1.06–1.11) more often received pharmacologic prophylaxis. Although women treated by high-volume surgeons more often received pharmacologic prophylaxis (OR 1.47, 95% CI 1.44–1.49), high hospital volume (OR 0.97, 95% CI 0.95–0.99) was associated with a lower rate of pharmacologic venous thromboembolism prophylaxis.
Given the importance of physician and hospital volume on prophylaxis, we performed an analysis stratified by year of diagnosis and surgical volume. The use of any prophylaxis increased from 48.0% to 61.1% at low-volume hospitals and from 53.7%–77.1% at high-volume facilities through the study. In 2000, 49.5% of patients treated by low-volume physicians and 57.4% treated by high-volume surgeons had prophylaxis. By 2010, this increased to 64.9% and 71.0%, respectively (Fig. 2). Pharmacologic prophylaxis increased from 12.4% to 21.8% at low-volume hospitals and from 7.3% to 27.5% at high-volume hospitals over time. Pharmacologic prophylaxis by low-volume physicians increased from 10.1% to 25.5% and from 9.8% to 25.0% for high-volume surgeons (Fig. 3).
Despite clear recommendations from evidence-based guidelines, our findings suggest that venous thromboembolism prophylaxis is underused in women undergoing abdominal and vaginal surgery for benign disease. Even in 2010, nearly one-third of women did not receive any form of prophylaxis. Encouragingly, use of prophylaxis, particularly pharmacologic prophylaxis, increased with time.
A number of studies have reported that compliance with venous thromboembolism prophylaxis is poor.11–13,16,21–24 The multinational venous thromboembolism risk and prophylaxis in the acute hospital care setting (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting [ENDORSE]) study examined over 68,000 patients from 32 countries. The investigators noted that only 59% of surgical patients and 40% of at-risk medical patients received some form of prophylaxis.12 When adherence to specific guideline-based recommendations for the appropriate timing and type of prophylaxis is examined, compliance is even lower.16,24 Administration of the appropriate type of venous thromboembolism prophylaxis preoperatively and for 24 hours after surgery as recommended by the US Surgical Care Improvement Project was noted in only 53% of patients in one analysis.24
The type of procedure performed appears to be the most important determinant of whether venous thromboembolism prophylaxis is used.12,13,16,21–23 Although data are limited, compliance with prophylaxis appears to be lower in gynecologic surgery than other high-risk specialties.13 One study reported that 54% of patients undergoing gynecologic or urologic procedures received prophylaxis compared with 86% for orthopedic procedures and 67% for abdominal and vascular surgery.13 In addition to the type of procedure performed, a multitude of other patient-related factors, including age, race, comorbidity, prior thromboembolic disease, and the presence of cancer, also appears to influence the use of prophylaxis.12,13,16,21–23 We noted that patients at higher risk for venous thromboembolism, older women and those with medical comorbidities, were more likely to receive prophylaxis, whereas African American women were 10% less likely than their white counterparts to receive prophylaxis.
Physician and hospital factors also had a strong influence on the allocation of prophylaxis. Patients treated by high-volume physicians, at rural hospitals, teaching hospitals, midsized facilities, and high-volume centers were more likely to receive some form of prophylaxis. Pharmacologic prophylaxis was more commonly given to patients at urban hospitals, teaching facilities, large hospitals, and to patients treated by high-volume surgeons. There is increasing recognition that in addition to patient characteristics, physician and systems factors play an important role in the care patients receive.25–27
Surgical volume was highly associated with use of prophylaxis. For many procedures, surgical volume has a strong influence on outcome.28,29 Although the volume–outcome paradigm is well described, the factors that underlie this finding remain poorly defined.15,18,19,30–33 Although higher volume may result in improved technical skill and better operative decision-making, volume is a surrogate for the entire process of care that a patient receives from the preoperative period through discharge. Improved perioperative care through adherence to evidence-based recommendations may be one of the factors contributing to the effect of volume on outcome. Our group previously demonstrated that for patients undergoing oncologic surgery, those patients treated by high-volume hospitals and surgeons were more likely to receive perioperative venous thromboembolism prophylaxis.34 In contrast, other studies examining the association between volume and guideline adherence have found only week associations.15,30–32
Our findings were interesting in that hospital volume appeared to be a driving factor in receipt of any prophylaxis, but physician volume seemed to have a greater influence on use of pharmacologic prophylaxis. One potential explanation for these findings is that hospital protocols influence overall use of prophylaxis but the specific choice to use pharmacologic prophylaxis rests with physicians. Further work to examine how physician characteristics influence the allocation of venous thromboembolism prophylaxis is clearly needed.
Although our study benefits from the inclusion of a large cohort of patients, we recognize a number of important limitations. Because the primary purpose of claims data is for billing, we cannot exclude the possibility that venous thromboembolism prophylaxis was misclassified in some patients. Because the Perspective database has been validated in a number of studies that have examined drug and device use, the number of patients misclassified is likely small.11,15,16,30 Among patients who developed a venous thromboembolism, it is difficult to determine if prophylactic anticoagulation was administered before the event or if only therapeutic anticoagulation was given after the diagnosis of the thromboembolism. Given the large sample, the proportion of patients misclassified is likely to be small. Although we were able to estimate the number of patients who received venous thromboembolism prophylaxis, it is not possible to examine the quality of prophylaxis. First, it is well known the compliance with mechanical prophylaxis among patients is poor.35 Second, although we reported the use of pharmacologic prophylaxis, this certainly does not ensure that the proper dose of the drug was administered throughout the hospitalization. In our analysis, we did not attempt to separate patients with contraindications to pharmacologic prophylaxis given that they would have been candidates for mechanical prophylaxis. Given the large number of patients, hospitals, and procedures in our analysis, it was difficult to correct for all possible clustering. It should be recognized that some studies in gynecologic surgery have reported that pharmacologic prophylaxis is associated with an increased risk of bleeding.7 Our study included a large sample size and it must be recognized that although some findings may have been statistically significant, they may not be clinically meaningful. Finally, although our data represent a sample from over 500 hospitals, our findings may not be generalizable to all hospitals and providers.
Our findings are concerning in that 40% of patients failed to receive prophylaxis. Although the use of prophylaxis increased, even in 2010, nearly one-third of women did not receive prophylaxis. The importance of venous thromboembolism prophylaxis has now gained increased recognition by both patients and payers. The Centers for Medicare and Medicaid Services now recognize DVT and pulmonary embolus after orthopedic procedures as a hospital-acquired condition and as such, its occurrence results in decreased reimbursement. To increase physician, hospital, and patient awareness, venous thromboembolism is now often used as a surrogate for quality. Venous thromboembolism rates are frequently publicly reported and prophylaxis is a common initiative used in pay-for-performance programs.36,37 There has also been a strong emphasis on more formalized venous thromboembolism prophylaxis protocols. The latest iteration of the American College of Chest Physicians thromboprophylaxis guidelines specifically calls for institution-wide thromboprophylaxis policies as well as strategies to increase adherence such as computerized decision systems, preprinted orders, and audits and feedback.1 Given the morbidity associated with venous thromboembolism as well as the fact events are highly preventable, our findings highlight the urgent need for further interventions to improve prophylaxis in women undergoing gynecologic surgery.
1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al.. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S–453S.
2. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S–400S.
3. Prevention of deep vein thrombosis and pulmonary embolism. ACOG Practice Bulletin No. 84. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:429–40.
4. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al.. Prevention of venous thromboembolism. Chest 2001;119:132S–75S.
5. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001;98:989–95.
6. Clarke-Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157–63.
7. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146–53.
8. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92–8.
9. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983;145:606–13.
10. Clarke-Pearson DL, DeLong ER, Synan IS, Creasman WT. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol 1984;64:689–94.
11. Amin AN, Stemkowski S, Lin J, Yang G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost 2008;99:796–7.
12. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al.. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study [published erratum appears in Lancet 2008;371:1914]. Lancet 2008;371:387–94.
13. Kakkar AK, Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Deslandes B, et al.. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg 2010;251:330–8.
14. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349–61.
15. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894–903.
16. Amin AN, Stemkowski S, Lin J, Yang G. Inpatient thromboprophylaxis use in US hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. J Hosp Med 2009;4:E15–21.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.
18. Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology 2007;69:871–5.
19. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg 2007;245:777–83.
20. Ritch JM, Kim JH, Lewin SN, Burke WM, Sun X, Herzog TJ, et al.. Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy. Obstet Gynecol 2011;117:1367–74.
21. Amin A, Stemkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol 2008;6:910–20.
22. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, et al.. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007;119:145–55.
23. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al.. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936–45.
24. Deitelzweig SB, Lin J, Hussein M, Battleman D. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis 2010;30:55–66.
25. Bilimoria KY, Phillips JD, Rock CE, Hayman A, Prystowsky JB, Bentrem DJ. Effect of surgeon training, specialization, and experience on outcomes for cancer surgery: a systematic review of the literature. Ann Surg Oncol 2009;16:1799–808.
26. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al.. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172–80.
27. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. J Natl Cancer Inst 2008;100:399–406.
28. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al.. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–37.
29. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117–27.
30. Auerbach AD, Hilton JF, Maselli J, Pekow PS, Rothberg MB, Lindenauer PK. Shop for quality or volume? Volume, quality, and outcomes of coronary artery bypass surgery. Ann Intern Med 2009;150:696–704.
31. Lindenauer PK, Behal R, Murray CK, Nsa W, Houck PM, Bratzler DW. Volume, quality of care, and outcome in pneumonia. Ann Intern Med 2006;144:262–9.
32. Shahian DM, O'Brien SM, Normand SL, Peterson ED, Edwards FH. Association of hospital coronary artery bypass volume with processes of care, mortality, morbidity, and the Society of Thoracic Surgeons composite quality score. J Thorac Cardiovasc Surg 2010;139:273–82.
33. Birkmeyer JD, Sun Y, Goldfaden A, Birkmeyer NJ, Stukel TA. Volume and process of care in high-risk cancer surgery. Cancer 2006;106:2476–81.
34. Wright JD, Lewin SN, Shah M, Burke WM, Lee SM, Sun X, et al.. Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. Ann Surg 2011;253:1140–6.
35. Bockheim HM, McAllen KJ, Baker R, Barletta JF. Mechanical prophylaxis to prevent venous thromboembolism in surgical patients: a prospective trial evaluating compliance. J Crit Care 2009;24:192–6.
36. Lindenauer PK, Remus D, Roman S, Rothberg MB, Benjamin EM, Ma A, et al.. Public reporting and pay for performance in hospital quality improvement. N Engl J Med 2007;356:486–96.
37. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006;43:322–30.
This article has been cited 3 time(s).
Gynecologic OncologyVenous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignanciesGynecologic Oncology
International Urogynecology JournalPerioperative management of gynecological surgery patients: does fellow involvement improve performance?International Urogynecology Journal
Obstetrics & GynecologyThromboprophylaxis for Gynecologic Surgery: Why Are We Stuck in 1975?Obstetrics & Gynecology
© 2011 The American College of Obstetricians and Gynecologists
ACOG MEMBER SUBSCRIPTION ACCESS
If you are an ACOG Fellow and have not logged in or registered to Obstetrics & Gynecology, please follow these step-by-step instructions to access journal content with your member subscription.